RD Global-Invamed has announced it has received CE marking to market the Extender drug-coated balloon (DCB) and Temren atherectomy with CTO catheter for treating arterial occlusions.
According to RD Global-Invamed, with the new Extender DCB and Temren atherectomy with CTO catheter, Invamed is expanding its venous product portfolio to include arterial treatments.
A company press release says that the Temren atherectomy with CTO catheter has a revolutionary tip design that can both cut and trim diseased tissue segment. It cuts, captures, and clears diseased tissue by aspiration with the Archimedes screw principle with one insertion. Temren treats a broad range of tissue types, from soft plaque to calcified arteries, and can be used for lesions above and below the knee. It has a novel tip design that centres the active tip of the device in vessel and minimises the risk of rupture.
The Extender DCB has a novel design to deliver paclitaxel into the diseased vessel segment.
Rasit Dinc, president of RD Global, stated, “Our experience and innovative approach to venous therapy has been successful in the treatment of venous insufficiency embolisation with VenaBlock and in deep vein thrombosis and pulmonary embolism treatment with hybrid thrombectomy therapy. Our innovative approach and experience has also provided a new approach to the treatment of arterial vascular diseases. In 2018 we will expand our arterial product portfolio with stent and graft products.”
Rasit Dinc also said, “RD Global is a research and development institute. Our aim is to develop new and better treatment options for all humans around the world. We are in a dynamic world and necessity for a new treatment options are increasing; our golden rule is, ‘Read, think, apply and follow’, in order to catch up with global needs.”